Cargando…

不同转移部位的非小细胞肺癌患者的生存时间比较

BACKGROUND AND OBJECTIVE: The purpose of this study is to compare the survival time of non-small cell lung cancer (NSCLC) patients with different organ metastasis. Among all cancers, the morbidity and mortality of lung cancer is the highest worldwide, which may caused by local recurrence and distant...

Descripción completa

Detalles Bibliográficos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 中国肺癌杂志编辑部 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6397941/
https://www.ncbi.nlm.nih.gov/pubmed/30827327
http://dx.doi.org/10.3779/j.issn.1009-3419.2019.02.05
_version_ 1783399494156550144
collection PubMed
description BACKGROUND AND OBJECTIVE: The purpose of this study is to compare the survival time of non-small cell lung cancer (NSCLC) patients with different organ metastasis. Among all cancers, the morbidity and mortality of lung cancer is the highest worldwide, which may caused by local recurrence and distant metastasis, and the location of metastasis may predict the prognosis of patients. METHODS: A total of 117, 542 patients with NSCLC diagnosed between 2010 and 2014 were enrolled from Surveillance, Epidemiology, and End Result (SEER) databases, and the relationship between distant metastasis and survival time was retrospectively analyzed. RESULTS: Of all the 117, 542 patients diagnosed with non-small cell lung cancer, 42, 071 (35.8%) patients had different degrees of distant metastasis during their medical history, including 26, 932 single organ metastases and 15, 139 multiple organ metastases, accounting for 64.0% and 36.0% of the metastatic patients respectively. Compared with patients with no metastasis, whose median survival time was 21 months, the median survival time of patients with metastases was 7 months (lung), 6 months (brain), 5 months (bone), 4 months (liver), and 3 months (multiple organ) respectively, and the difference was significant (P < 0.001, except liver vs multiple organ P=0.650); Most patients with NSCLC (88.4%) eventually died of lung cancer. CONCLUSION: Distant metastasis of NSCLC patients indicates poor prognosis. In NSCLC patients with single organ metastasis, the prognosis of lung metastasis is the best, and liver metastasis is the worst, and multiple organ metastasis is worse than single organ metastasis.
format Online
Article
Text
id pubmed-6397941
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher 中国肺癌杂志编辑部
record_format MEDLINE/PubMed
spelling pubmed-63979412019-04-05 不同转移部位的非小细胞肺癌患者的生存时间比较 Zhongguo Fei Ai Za Zhi 临床研究 BACKGROUND AND OBJECTIVE: The purpose of this study is to compare the survival time of non-small cell lung cancer (NSCLC) patients with different organ metastasis. Among all cancers, the morbidity and mortality of lung cancer is the highest worldwide, which may caused by local recurrence and distant metastasis, and the location of metastasis may predict the prognosis of patients. METHODS: A total of 117, 542 patients with NSCLC diagnosed between 2010 and 2014 were enrolled from Surveillance, Epidemiology, and End Result (SEER) databases, and the relationship between distant metastasis and survival time was retrospectively analyzed. RESULTS: Of all the 117, 542 patients diagnosed with non-small cell lung cancer, 42, 071 (35.8%) patients had different degrees of distant metastasis during their medical history, including 26, 932 single organ metastases and 15, 139 multiple organ metastases, accounting for 64.0% and 36.0% of the metastatic patients respectively. Compared with patients with no metastasis, whose median survival time was 21 months, the median survival time of patients with metastases was 7 months (lung), 6 months (brain), 5 months (bone), 4 months (liver), and 3 months (multiple organ) respectively, and the difference was significant (P < 0.001, except liver vs multiple organ P=0.650); Most patients with NSCLC (88.4%) eventually died of lung cancer. CONCLUSION: Distant metastasis of NSCLC patients indicates poor prognosis. In NSCLC patients with single organ metastasis, the prognosis of lung metastasis is the best, and liver metastasis is the worst, and multiple organ metastasis is worse than single organ metastasis. 中国肺癌杂志编辑部 2019-02-20 /pmc/articles/PMC6397941/ /pubmed/30827327 http://dx.doi.org/10.3779/j.issn.1009-3419.2019.02.05 Text en 版权所有©《中国肺癌杂志》编辑部2019 https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 3.0) License. See: https://creativecommons.org/licenses/by/3.0/
spellingShingle 临床研究
不同转移部位的非小细胞肺癌患者的生存时间比较
title 不同转移部位的非小细胞肺癌患者的生存时间比较
title_full 不同转移部位的非小细胞肺癌患者的生存时间比较
title_fullStr 不同转移部位的非小细胞肺癌患者的生存时间比较
title_full_unstemmed 不同转移部位的非小细胞肺癌患者的生存时间比较
title_short 不同转移部位的非小细胞肺癌患者的生存时间比较
title_sort 不同转移部位的非小细胞肺癌患者的生存时间比较
topic 临床研究
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6397941/
https://www.ncbi.nlm.nih.gov/pubmed/30827327
http://dx.doi.org/10.3779/j.issn.1009-3419.2019.02.05
work_keys_str_mv AT bùtóngzhuǎnyíbùwèidefēixiǎoxìbāofèiáihuànzhědeshēngcúnshíjiānbǐjiào
AT bùtóngzhuǎnyíbùwèidefēixiǎoxìbāofèiáihuànzhědeshēngcúnshíjiānbǐjiào
AT bùtóngzhuǎnyíbùwèidefēixiǎoxìbāofèiáihuànzhědeshēngcúnshíjiānbǐjiào
AT bùtóngzhuǎnyíbùwèidefēixiǎoxìbāofèiáihuànzhědeshēngcúnshíjiānbǐjiào
AT bùtóngzhuǎnyíbùwèidefēixiǎoxìbāofèiáihuànzhědeshēngcúnshíjiānbǐjiào
AT bùtóngzhuǎnyíbùwèidefēixiǎoxìbāofèiáihuànzhědeshēngcúnshíjiānbǐjiào